Who we are.

Join the fight against pancreatic cancer! The 2015 Pancreatic Cancer Research Walk is Sunday, November 1st at Sloan's Lake Park, Denver, CO.

All the money raised goes directly to pancreatic cancer research thanks to the Lustgarten Foundation!

Monday, April 15, 2013

Provenge and Intratumoral Chemo for Pancreatic Cancer


Provenge
Provenge is a treatment for asymptomatic or minimally symptomatic, metastatic, castrate-resistent (hormone refractory) prostate cancer. The mets can only be bone or soft tissue, and the patient can't be on narcotics for cancer-related pain. The patient must have had no chemo in the previous three months or steroids in 28 days, and must have an ECOG status of 0-1 (e.g., generally feels okay). According to Dendreon and research studies, Provenge is the only prostate drug to extend survival for this particular type of prostate cancer beyond two years. It is also the first FDA-approved immunotherapy vaccine.

Intratumoral Chemo for Pancreatic Cancer
At Cancer Treatment Centers of America in Tulsa, where appropriate, an endoscopic ultrasound (EUS) is used to reach the pancreas and inject chemotherapy directly into the tumor. This procedure is done once a week for four weeks, with a CT scan completed before the first treatment and after the final one to gauge results. Pancreatic intratumoral chemotherapy is an adjuvant treatment, so patients can still receive normal chemotherapy, treatment, etc., while receiving this procedure.

http://www.hopenavigators.com/tipping-the-scales/cutting-edge-technology/provenge-and-intratumoral-chemo-for-pancreatic-cancer

No comments:

Post a Comment